# Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

> **NCT02944357** · NA · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Infiltrating Bladder Urothelial Carcinoma
- Stage II Bladder Urothelial Carcinoma
- Stage III Bladder Urothelial Carcinoma
- Stage IV Bladder Urothelial Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine Hydrochloride
- **PROCEDURE:** Radical Cystectomy
- **BIOLOGICAL:** Tumor Cell-Derived Vaccine Therapy

## Key facts

- **NCT ID:** NCT02944357
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2017-09-05
- **Final completion:** 2017-09-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02944357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02944357, "Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02944357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*